Found 5 matching trials
Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1 PHASE2 Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attach...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet PHASE1 This 2-part study will determine the bioavailability of BMS-626529 in healt...
Show More Location
GSK Investigational Site
Learn More & Join Trial
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects PHASE1 An oral dose in healthy subjects to determine the relative bioavailabilty o...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients PHASE3 The purpose of this study is to determine whether the BMS Attachment Inhibi...
Show More Status
Active Not Recruiting
Location
GSK Investigational Site
Learn More & Join Trial
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections PHASE2 The purpose of this study is to assess the safety, efficacy, tolerability a...
Show More Location
GSK Investigational Site
Learn More & Join Trial